302 related articles for article (PubMed ID: 30971457)
1. Mortality in IgA Nephropathy: A Nationwide Population-Based Cohort Study.
Jarrick S; Lundberg S; Welander A; Carrero JJ; Höijer J; Bottai M; Ludvigsson JF
J Am Soc Nephrol; 2019 May; 30(5):866-876. PubMed ID: 30971457
[TBL] [Abstract][Full Text] [Related]
2. Immunoglobulin A nephropathy and ischemic heart disease: a nationwide population-based cohort study.
Jarrick S; Lundberg S; Sundström J; Symreng A; Warnqvist A; Ludvigsson JF
BMC Nephrol; 2021 May; 22(1):165. PubMed ID: 33952193
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: A multi-centre registry study.
Zhang L; Liu X; Pascoe EM; Badve SV; Boudville NC; Clayton PA; De Zoysa J; Hawley CM; Kanellis J; McDonald SP; Peh CA; Polkinghorne KR; Johnson DW
Nephrology (Carlton); 2016 May; 21(5):387-96. PubMed ID: 26393772
[TBL] [Abstract][Full Text] [Related]
4. Cancer risk in patients with immunoglobulin A nephropathy: a Swedish population-based cohort study.
Rehnberg J; Ludvigsson JF; Carrero JJ; Emilsson L
Nephrol Dial Transplant; 2022 Mar; 37(4):749-759. PubMed ID: 34788864
[TBL] [Abstract][Full Text] [Related]
5. Addition of eGFR and Age Improves the Prognostic Absolute Renal Risk-Model in 1,134 Norwegian Patients with IgA Nephropathy.
Knoop T; Vågane AM; Vikse BE; Svarstad E; Magnúsdóttir BT; Leh S; Varberg Reisæter A; Bjørneklett R
Am J Nephrol; 2015; 41(3):210-9. PubMed ID: 25872002
[TBL] [Abstract][Full Text] [Related]
6. Patient characteristics and outcomes by GN subtype in ESRD.
O'Shaughnessy MM; Montez-Rath ME; Lafayette RA; Winkelmayer WC
Clin J Am Soc Nephrol; 2015 Jul; 10(7):1170-8. PubMed ID: 26092830
[TBL] [Abstract][Full Text] [Related]
7. Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease.
Barbour SJ; Cattran DC; Kim SJ; Levin A; Wald R; Hladunewich MA; Reich HN
Kidney Int; 2013 Nov; 84(5):1017-24. PubMed ID: 23739233
[TBL] [Abstract][Full Text] [Related]
8. Mortality of IgA nephropathy patients: a single center experience over 30 years.
Lee H; Kim DK; Oh KH; Joo KW; Kim YS; Chae DW; Kim S; Chin HJ
PLoS One; 2012; 7(12):e51225. PubMed ID: 23226568
[TBL] [Abstract][Full Text] [Related]
9. Long-term risk of ESRD in IgAN; validation of Japanese prognostic model in a Norwegian cohort.
Bjørneklett R; Vikse BE; Bostad L; Leivestad T; Iversen BM
Nephrol Dial Transplant; 2012 Apr; 27(4):1485-91. PubMed ID: 21821835
[TBL] [Abstract][Full Text] [Related]
10. Predictors of outcome in paediatric IgA nephropathy with regard to clinical and histopathological variables (Oxford classification).
Edström Halling S; Söderberg MP; Berg UB
Nephrol Dial Transplant; 2012 Feb; 27(2):715-22. PubMed ID: 21750154
[TBL] [Abstract][Full Text] [Related]
11. Kidney Failure Risk Prediction Equations in IgA Nephropathy: A Multicenter Risk Assessment Study in Chinese Patients.
Xie J; Lv J; Wang W; Li G; Liu Z; Chen H; Xu F; Sun J; Ouyang Y; Zhang X; Yang M; Shi M; Zhang W; Ren H; Kiryluk K; Zhang H; Chen N
Am J Kidney Dis; 2018 Sep; 72(3):371-380. PubMed ID: 29555434
[TBL] [Abstract][Full Text] [Related]
12. A validation study of crescents in predicting ESRD in patients with IgA nephropathy.
Zhang X; Shi S; Ouyang Y; Yang M; Shi M; Pan X; Lv J; Wang Z; Ren H; Shen P; Wang W; Zhang H; Xie J; Chen N
J Transl Med; 2018 May; 16(1):115. PubMed ID: 29724226
[TBL] [Abstract][Full Text] [Related]
13. Serum immunoglobulin G provides early risk prediction in immunoglobulin A nephropathy.
Liu D; You J; Liu Y; Tang X; Tan X; Xia M; Wu L; Chen G; He L; Zhu X; Liu H
Int Immunopharmacol; 2019 Jan; 66():13-18. PubMed ID: 30415190
[TBL] [Abstract][Full Text] [Related]
14. Increased serum uric acid levels are associated to renal arteriolopathy and predict poor outcome in IgA nephropathy.
Russo E; Drovandi S; Salvidio G; Verzola D; Esposito P; Garibotto G; Viazzi F
Nutr Metab Cardiovasc Dis; 2020 Nov; 30(12):2343-2350. PubMed ID: 32912790
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival of patients with IgA nephropathy after dialysis therapy.
Komatsu H; Kikuchi M; Nakagawa H; Fukuda A; Iwakiri T; Toida T; Sato Y; Kitamura K; Fujimoto S
Kidney Blood Press Res; 2013; 37(6):649-56. PubMed ID: 24356555
[TBL] [Abstract][Full Text] [Related]
16. CD147 renal expression as a biomarker for progressive IgAN.
Sun S; Zhao A; Li R; Du R; He L; Sun W; Wang H; Huang C
J Nephrol; 2015 Jun; 28(3):307-14. PubMed ID: 25510296
[TBL] [Abstract][Full Text] [Related]
17. IgA nephropathy associated with thin basement membrane with or without inflammatory disease: getting a different prognosis?
Xu G; Tu W; Yu C; Xu C; Hu X; Wu W
Ren Fail; 2009; 31(6):452-6. PubMed ID: 19839821
[TBL] [Abstract][Full Text] [Related]
18. Lower serum bilirubin is associated with poor renal outcome in IgA nephropathy patients.
Jiang Z; Tan J; Wang S; Dong L; Han X; Tang Y; Qin W
Int J Med Sci; 2021; 18(13):2964-2970. PubMed ID: 34220324
[No Abstract] [Full Text] [Related]
19. Recurrence of IgA nephropathy after kidney transplantation in steroid continuation versus early steroid-withdrawal regimens: a retrospective analysis of the UNOS/OPTN database.
Leeaphorn N; Garg N; Khankin EV; Cardarelli F; Pavlakis M
Transpl Int; 2018 Feb; 31(2):175-186. PubMed ID: 28926143
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes, when matched at presentation, do not vary between adult-onset Henöch-Schönlein purpura nephritis and IgA nephropathy.
Oh HJ; Ahn SV; Yoo DE; Kim SJ; Shin DH; Lee MJ; Kim HR; Park JT; Yoo TH; Kang SW; Choi KH; Han SH
Kidney Int; 2012 Dec; 82(12):1304-12. PubMed ID: 22895518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
